[Targeted radionuclide therapy for castration-resistant prostate cancer]

Katsumasa Nakamura, Ohga Saiji, Tomonari Sasaki, Shingo Baba, Hiroshi Honda

Research output: Contribution to journalReview articlepeer-review


Although patients with castration-resistant prostate cancer frequently have metastases to the bone, they have a relatively favorable prognosis. Therefore, it is important to keep or improve the level of patient's quality of life. The use of strontium-89 for the management of the pain from bone metastasis was approved in 2007 in Japan. A new bone-targeting radiopharmaceuticals using radium-223 is also promising, because a randomized trial showed an overall survival advantage of radium-223 in prostate patients with bone metastases. In this review, we summarize the role of targeted radionuclide therapy for castration-resistant prostate cancer, focusing on strontium-89 and radium-223.

Original languageEnglish
Pages (from-to)2181-2185
Number of pages5
JournalNihon rinsho. Japanese journal of clinical medicine
Issue number12
Publication statusPublished - Dec 1 2014

All Science Journal Classification (ASJC) codes

  • Medicine(all)


Dive into the research topics of '[Targeted radionuclide therapy for castration-resistant prostate cancer]'. Together they form a unique fingerprint.

Cite this